Clinical Trials Logo

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

NCT number NCT03948269
Other study ID # Southeast Menopausal Protocol
Secondary ID
Status Enrolling by invitation
Phase N/A
First received
Last updated
Start date June 1, 2018
Est. completion date August 31, 2020

Study information

Verified date May 2019
Source Southeast University, China
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Background: Menopause syndrome generally occurs with and is related to psychological problems. However, Internet- and mobile-based group treatment (imGT) may improve women's physiological and psychological conditions.

Objective: To investigate the efficacy of group treatment with or without Internet- and mobile-based treatment of menopause, mood swings and quality of life status.

Methods: This protocol is for a randomized controlled clinical trial with a sample of 144 menopausal women divided into 2 groups: imGT and face-to-face group treatment (ffGT). The primary outcome will be the menopausal symptom improvement of the two groups, as assessed by Greene Climacteric Scale. The secondary outcomes will be quality of life, assessed by the Short Form 36 Health Survey Questionnaire; insomnia, assessed by the Pittsburgh Sleep Quality Inventory; anxiety, assessed by the Hamilton Anxiety Rating Scale; and therapeutic alliance, assessed by the Working Alliance Inventory-Short Revised. imGT will be performed once a week for 1.5 hours for 10 weeks with a daily Punched-in on the WeChat App; ffGT will be performed once a week for 1.5 hours for 10 weeks. All outcomes will be assessed at baseline, at a post-intervention evaluation (week 10), and at a follow-up evaluation (week 22).

Discussion: This study will be the first clinical trial to examine the effects of imGT on menopausal women in China. If imGT is found to be equivalent to or superior to ffGT, it will facilitate easier access to menopausal health services, which may be feasible to offer to other medical institution.


Recruitment information / eligibility

Status Enrolling by invitation
Enrollment 140
Est. completion date August 31, 2020
Est. primary completion date March 31, 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 40 Years to 60 Years
Eligibility Inclusion Criteria:

- aged 40~60, in menopausal transition or post-menopause, according to the STRAW +10 definition

- have Internet access

- have mobile phone access

- have sufficient knowledge of the Chinese language

- have scored in the clinical range for menopause syndrome from the psychiatric interview

- have signed a consent form that will be provided to eligible participants.

Exclusion Criteria:

- not completing informed consent

- presence of any of the following diseases: hyperthyroidism, coronary atherosclerotic heart disease, hypertension (BP=140/90 mmHg), pheochromocytoma, neurasthenia, psychosis, or other diseases closely related to the main disease

- troublesome drinking

- drug use (hypnotics or hormone therapy) in the past 14 days, which might affect mood.

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
group behavioral cognitive therapy
First, we will establish a WeChat group containing the imGT group members and psychiatrists, in which everyone can talk instantly. The interactive treatments will be conducted every Friday evening for a duration of 1.5 hours via text, audio or video messaging. Table 1 summarizes the module topics and provides detailed information on the treatment program. All modules will be saved for repeated viewing after completion. Second, we will establish another WeChat program named Punched-in which participants report on aspects of their everyday life such as diet, sports, readings or mood, according to the plan made by psychiatrists, via text, audio, photo or video message. This program will only be visible to and able to be commented on by participants and psychiatrists.

Locations

Country Name City State
China the Affiliated Obstetrics and Gynaecology Hospital of Nanjing Medical University Nanjing Jiangsu

Sponsors (2)

Lead Sponsor Collaborator
Southeast University, China The Affiliated Obstetrics and Gynecology Hospital of Nanjing Medical University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Greene Climacteric Scale Greene Climacteric Scale is used for evaluating menopausal symptoms. It contains 21 questions covering 5 domains: anxiety, depression, somatic symptoms, vasomotor symptoms, and sexual function. Each question is answered on a 4-point Likert scale. The answers to all 21 questions are summed to give a total quality-of-life measure; a higher score indicates a worse quality of life. According to the hypothesis and PRO-specific domains of this trial, vasomotor symptoms, anxiety and depression will be analysed specifically. The Chinese version of this questionnaire has a high validation (0.90), and the Cronbach's alpha coefficient is 0.95, while its test-retest reliability is 0.94 (P <0.01). week 0
Primary Greene Climacteric Scale Menopause symptoms after 10 sessions of group cognitive behavioral therapy week 10
Primary Greene Climacteric Scale Menopause symptoms of one follow-up meeting week 22
Secondary The Short Form 36 Health Survey Questionnaire The Short Form 36 Health Survey Questionnaire (SF36) is widely used for evaluating the potential benefits of healthcare interventions. It is comprised of eight dimensions (including physical functioning, social functioning, role limitations, mental health, energy/vitality, pain, general health perceptions), and the score ranges from 0 to 100, where better health achieves higher scores. This questionnaire was chosen because of the validation of the Chinese version with a sensitivity of 0.72~0.88 and specificity of 87.5%~100%. week 0
Secondary The Short Form 36 Health Survey Questionnaire Quality of life week 10
Secondary The Short Form 36 Health Survey Questionnaire Quality of life week 22
Secondary Pittsburgh Sleep Quality Index The Pittsburgh Sleep Quality Index (PSQI) is a self-rating inventory that evaluates sleep quality and disturbances within a 4-week time interval. It comprises 19 individual items with a global score ranging from 0 to 21. The correlation coefficient of PSQI for t-test reliability was 0.87. A Chinese PSQI score >7 yielded a sensitivity of 98.3% and specificity of 90.2% in distinguishing between good and poor sleepers (kappa= 0.89, p<0.01) week 0
Secondary Pittsburgh Sleep Quality Index Insomnia week 10
Secondary Pittsburgh Sleep Quality Index Insomnia week 22
Secondary The Hamilton Anxiety Rating Scale The Hamilton Anxiety Rating Scale (HAM-A) is a rating scale developed to measure the symptoms of anxiety neurosis. It is a semi-structured clinician-rated interview consisting of 14 items that measure both psychological anxiety and somatic anxiety. A 5-point scale ranging from 0 (not present) to 4 (severe) is used, where the total severity score is 0-56; <17 indicates mild anxiety and 25-30 is considered moderate-severe. The Chinese version of HAM-A will be used in this study. week 0, 10, 22
Secondary The Hamilton Anxiety Rating Scale Anxiety week 10
Secondary The Hamilton Anxiety Rating Scale Anxiety week 22
Secondary The Working Alliance Inventory-Short Revised The Working Alliance Inventory-Short Revised (WAI-SR) provides an assessment of the therapeutic alliance and contains 12 items with three dimensions of working alliance: agreement on the tasks of therapy, agreement on the goals of therapy and development of an affective bond between client and therapist. Items are rated on a 5-point scale (range from 1= "never" to 5= "always"). week 0, 10
Secondary The Working Alliance Inventory-Short Revised Therapeutic alliance week 10
Secondary Client Satisfaction Qestionnaire-8 (CSQ-8) Treatment satisfaction will be measured by the Client Satisfaction Qestionnaire-8 (CSQ-8), which evaluates the service utilization and psychotherapy outcome measures with high internal consistency (coefficient a = .91). week 10
See also
  Status Clinical Trial Phase
Completed NCT01741974 - Study of Anti-atherosclerotic and Estrogen-like Activity of Karinat in Perimenopausal Women Phase 3
Not yet recruiting NCT05522621 - A Muticenter Clinical Study of Chinese Herbal Compound TJAOA102 in Alleviating Menopausal Syndrome Early Phase 1
Completed NCT01046643 - Early Menopause Hormone Treatment and Cognition N/A
Active, not recruiting NCT00694733 - Regulation of Cortisol Metabolism and Fat Patterning N/A
Completed NCT05759936 - 4-week Seaweed Supplementation on Menopause Symptoms and Psychological Wellbeing N/A
Completed NCT05266079 - Comparison Study for Perimenopausal Syndrome With Chinese Herbal Medicine N/A
Completed NCT04520542 - The Effect of Acupressure Application on Menopausal Symptoms N/A
Completed NCT02749747 - Sulpiride Versus Placebo for Reducting Hot Flushes During Climacteric Phase 3
Completed NCT01849172 - Effect and Safety of Electroacupuncture for Symptoms of Menopausal Transition N/A
Recruiting NCT04031456 - Autologous PRP Infusion May Restore Ovarian Function and May Promote Folliculogenesis in POI Patients Phase 2/Phase 3
Recruiting NCT02294500 - Cohort Study to Evaluate Ovarian Function N/A
Completed NCT02467673 - Nanoparticulate Versus Micronized Steroids Delivery for Transdermal Hormone Replacement Therapy Phase 2
Recruiting NCT05280028 - HRT on Overactive Bladder Symptoms, Sexual Function, Depressive Symptoms, Autonomic Function, and Arterial Stiffness
Completed NCT00289926 - Efficacy and Safety of Oral DHEA Therapy for Postmenopausal Women on Sexual Function, Wellbeing and Vasomotor Symptoms Phase 3
Recruiting NCT01698164 - Multi-centre Clinical Trial on Hormone Replacement Treatment in China Phase 4
Completed NCT05463081 - Clinical Trial of "Magic Gyno" Laser Device N/A
Completed NCT00933725 - Efficacy and Safety of Traditional Chinese Medicine Intervention for Women With Menopausal Syndrome Phase 3
Enrolling by invitation NCT02001402 - Chinese Health Investigation of Nurse Aging N/A
Recruiting NCT04726254 - The JULI Registry--Hemp and Cannabis Observational Registry
Completed NCT01931748 - A Randomized, Double-Blind, Parallel, Non-Inferiority, Multicenter Trial Evaluate the Efficacy and Safety of UNCNT Compared to MELSMON in Female With Menopausal Syndrome Phase 3